Literature DB >> 30361190

West syndrome, developmental and epileptic encephalopathy, and severe CNS disorder associated with WWOX mutations.

Qudsia Shaukat1, Jozef Hertecant2, Ayman W El-Hattab2, Bassam R Ali3, Jehan Suleiman4.   

Abstract

Mutations in the WWOX gene have been reported in a number of patients with various neurological disorders including spino-cerebellar ataxia, intellectual disability, epilepsy, and epileptic encephalopathy. We aimed to study the clinical, electrographic, and imaging features of two new cases with WWOX mutations and compare them to previously reported cases with WWOX mutations. We assessed two unrelated children from two consanguineous families who had severe neurological disorder including early-onset spastic quadriplegia, profound developmental delay, epilepsy, and West syndrome. Based on whole-exome sequencing, we identified homozygous null mutations in WWOX in both children, and further addressed the genotype-phenotype correlation. In addition, we provide a detailed review of the previously reported cases of WWOX-related neurological disorders and compare them to the children in this report. The findings in this report expand the clinical phenotype associated with WWOX mutations and confirm a well characterised severe central nervous system disorder in association with biallelic null mutations in WWOX. This syndrome consists of profound psychomotor delay, early-onset spastic quadriplegia, and refractory epilepsy including epileptic encephalopathy, acquired microcephaly, and growth restriction. This can be associated with progressive brain atrophy, suggestive of neurodegeneration. Identification of this phenotype by clinicians may help with early diagnosis and appropriate genetic counselling.

Entities:  

Keywords:  WWOX; West syndrome; epileptic encephalopathy; intellectual disability; microcephaly; spasticity

Mesh:

Substances:

Year:  2018        PMID: 30361190     DOI: 10.1684/epd.2018.1005

Source DB:  PubMed          Journal:  Epileptic Disord        ISSN: 1294-9361            Impact factor:   1.819


  6 in total

Review 1.  The WWOX gene in brain development and pathology.

Authors:  K Kośla; Ż Kałuzińska; A K Bednarek
Journal:  Exp Biol Med (Maywood)       Date:  2020-05-09

2.  Neonatal neuronal WWOX gene therapy rescues Wwox null phenotypes.

Authors:  Srinivasarao Repudi; Irina Kustanovich; Sara Abu-Swai; Shani Stern; Rami I Aqeilan
Journal:  EMBO Mol Med       Date:  2021-11-07       Impact factor: 12.137

Review 3.  WWOX-Related Neurodevelopmental Disorders: Models and Future Perspectives.

Authors:  Daniel J Steinberg; Rami I Aqeilan
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

4.  A Phenotypic-Driven Approach for the Diagnosis of WOREE Syndrome.

Authors:  Antonella Riva; Giulia Nobile; Thea Giacomini; Marzia Ognibene; Marcello Scala; Ganna Balagura; Francesca Madia; Andrea Accogli; Ferruccio Romano; Domenico Tortora; Mariasavina Severino; Paolo Scudieri; Simona Baldassari; Ilaria Musante; Paolo Uva; Vincenzo Salpietro; Annalaura Torella; Vincenzo Nigro; Valeria Capra; Lino Nobili; Pasquale Striano; Maria Margherita Mancardi; Federico Zara; Michele Iacomino
Journal:  Front Pediatr       Date:  2022-04-29       Impact factor: 3.418

5.  Normal cells repel WWOX-negative or -dysfunctional cancer cells via WWOX cell surface epitope 286-299.

Authors:  Yu-An Chen; Yong-Da Sie; Tsung-Yun Liu; Hsiang-Ling Kuo; Pei-Yi Chou; Yu-Jie Chen; Kuan-Ting Lee; Pin-Jun Chen; Shur-Tzu Chen; Nan-Shan Chang
Journal:  Commun Biol       Date:  2021-06-17

6.  Rare Variants in 48 Genes Account for 42% of Cases of Epilepsy With or Without Neurodevelopmental Delay in 246 Pediatric Patients.

Authors:  Ana Fernández-Marmiesse; Iria Roca; Felícitas Díaz-Flores; Verónica Cantarín; Mª Socorro Pérez-Poyato; Ana Fontalba; Francisco Laranjeira; Sofia Quintans; Oana Moldovan; Blanca Felgueroso; Montserrat Rodríguez-Pedreira; Rogelio Simón; Ana Camacho; Pilar Quijada; Salvador Ibanez-Mico; Mª Rosario Domingno; Carmen Benito; Rocío Calvo; Antonia Pérez-Cejas; Mª Llanos Carrasco; Feliciano Ramos; Mª Luz Couce; Mª Luz Ruiz-Falcó; Luis Gutierrez-Solana; Margarita Martínez-Atienza
Journal:  Front Neurosci       Date:  2019-11-08       Impact factor: 4.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.